ArticleInternational journal of cardiology. Cardiovascular risk and prevention2026
Cardiovascular magnetic resonance-derived left atrioventricular coupling index for predicting adverse cardiac outcomes in patients with ischemic cardiomyopathy.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risk stratification in ischemic cardiomyopathy (ICM) traditionally relies on left ventricular ejection fraction (LVEF), which may not fully demonstrate the complex interplay between atrium and ventricle. The left atrioventricular coupling index (LACI) has emerged as a promising integrative marker. This study evaluated the prognostic value of cardiovascular magnetic resonance (CMR)-derived LACI in patients with ICM. Methods: This retrospective cohort study included 276 patients with ICM (mean age 65 ± 12 years and 80% male) who underwent CMR. LACI was calculated as LAEDV/LVEDV. The primary endpoint was a composite of cardiovascular mortality, non-fatal myocardial infarction, heart failure hospitalization (HFH), and major ventricular arrhythmic events. Secondary endpoints included individual components of the primary endpoint and all-cause mortality. Optimal LACI cut-off values were determined using receiver operating characteristic (ROC) analysis. Results: During a median follow-up of 3.2 years, the primary endpoint occurred in 100 patients (36.2%). The optimal LACI cut-off for predicting the primary outcome was 0.35. Patients with LACI ≥ 0.35 had a significantly higher incidence of the primary outcome compared to those below the threshold (52.3% vs. 31.3%; p = 0.002). In multivariate Cox regression analysis, LACI ≥0.35 was an independent predictor of the primary outcome (aHR 1.83; 95%CI 1.06-3.16; p = 0.029). Among secondary endpoints, LACI ≥ 0.38 was strongly associated with HFH (aHR 3.33; 95%CI 1.58-6.72; p < 0.001), though it did not reach statistical significance for mortality. Conclusions: CMR-derived LACI is an independent predictor of adverse cardiovascular outcomes, particularly HFH, in patients with ICM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.